Literature DB >> 18201757

Sexual incentive motivation in old male rats: the effects of sildenafil and a compound (Impaza) stimulating endothelial NO synthase.

Xi Chu1, Anders Agmo.   

Abstract

Several proerectile drugs act on the nitric oxide-cyclic guanosine monophosphate pathway, which is known to influence rat copulatory behavior. In the present study we evaluated the effects of two proerectile compounds, one (Impaza) acting on endothelial nitric oxide synthase, and the other (sildenafil) on phosphodiesterase 5, on sexual incentive motivation in male rats displaying a spontaneously low level of motivation and copulatory behavior. About 20 months old male Fisher 344 rats were tested in a procedure for evaluating the intensity of sexual incentive motivation and in standard mating tests. For comparison, a group of young (about 4 months) Fisher 344 males was tested in parallel. This group did not receive any drug treatment. Impaza was administered in two doses, daily for 28 days, and sildenafil was given at a dose of 3 mg/kg twice a week during 28 days. Tests for sexual incentive motivation and copulatory behavior were performed immediately before the beginning of drug treatments, and on days 7, 14 and 28 of treatment. All treatment groups displayed a very low level of copulatory behavior and a sexually receptive female was not a more powerful incentive than another male at the tests performed before and on days 7 and 14 of treatment. On day 28 of treatment, the group treated with Impaza, 3 ml, displayed a preference for the sexually receptive female, while no such preference was found in the other groups. Furthermore, the preference score was above that of controls in this group. Both Impaza, 3 ml, and sildenafil reduced approach to the male in the test for sexual incentive motivation, suggesting that social motivation was reduced. These data suggest that compounds affecting the nitric oxide-cyclic guanosine monophosphate pathway may modify both sexual and social motivation in old rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201757     DOI: 10.1016/j.pbb.2007.12.012

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Zaprinast, a phosphodiesterase type-5 inhibitor, alters paced mating behavior in female rats.

Authors:  Ann S Clark; Sarah H Meerts; Fay A Guarraci
Journal:  Physiol Behav       Date:  2008-10-29

2.  Effects of chronic treatment with the eNOS stimulator Impaza on penis length and sexual behaviors in rats with a high baseline of sexual activity.

Authors:  X Chu; E S Zhavbert; J L Dugina; I A Kheyfets; S A Sergeeva; O I Epstein; A Agmo
Journal:  Int J Impot Res       Date:  2013-03-14       Impact factor: 2.896

3.  The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone.

Authors:  Danielle Bailbé; Erwann Philippe; Evgeniy Gorbunov; Sergey Tarasov; Oleg Epstein; Bernard Portha
Journal:  J Diabetes Res       Date:  2013-05-08       Impact factor: 4.011

4.  Use of Piezoelectric Immunosensors for Detection of Interferon-Gamma Interaction with Specific Antibodies in the Presence of Released-Active Forms of Antibodies to Interferon-Gamma.

Authors:  Elena Don; Olga Farafonova; Suzanna Pokhil; Darya Barykina; Marina Nikiforova; Darya Shulga; Alena Borshcheva; Sergey Tarasov; Tatyana Ermolaeva; Oleg Epstein
Journal:  Sensors (Basel)       Date:  2016-01-20       Impact factor: 3.576

5.  In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form.

Authors:  Evgeniy A Gorbunov; Irina A Ertuzun; Evgeniya V Kachaeva; Sergey A Tarasov; Oleg I Epstein
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-03       Impact factor: 2.570

6.  Dose-Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light-Dark Test in Mice.

Authors:  Elena V Kardash; Irina A Ertuzun; Gul'nara R Khakimova; Andrey N Kolyadin; Sergey A Tarasov; Stéphanie Wagner; Emile Andriambeloson; Vladimir T Ivashkin; Oleg I Epstein
Journal:  Dose Response       Date:  2018-06-26       Impact factor: 2.658

7.  Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial.

Authors:  Dmitry Pushkar; Andrey Vinarov; Leonid Spivak; Konstantin Kolontarev; Mikhail Putilovskiy; Elena Andrianova; Oleg Epstein
Journal:  Cent European J Urol       Date:  2018-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.